2446618-18-2
Chemical Structure
Taragarestrant meglumine
Synonym(s): D-0502 meglumine
- CAS No.: 2446618-18-2
- Formula:C32H42Cl2FN3O7
- Molecular Weight:670.60
IUPAC Name: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol (E)-3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylate
InChIKey: QLOWUROBGXPIGD-DAIKAQOVSA-N
SMILES: CC(C)(F)CN1[C@@](C2=C(C=C(C=C2Cl)/C=C/C(O)=O)Cl)([H])C3=C(C[C@H]1C)C4=CC=CC=C4N3.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC
Biological Activity: Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taragarestrant meglumine | 99.33% | Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776.
- [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical.
